Major interaction on record — check this product against your medications before combining. Check your meds →
Dietary supplement

Resveratrol Ingredients & Drug Interactions

by NutraMedix

Resveratrol label
See full label image
Capsule Category: Other Combinations
Most serious interaction: Major
Clinical methodology reviewed by · Updated Sep 23, 2026 · Label data from the NIH DSLD
What is this page for?

First and foremost: checking Resveratrol against your medications. The heart of this page is the interaction checker and the full interaction report — how this product’s ingredients may interact with prescription and over-the-counter medicines you may be taking.

Around that, we add a pharmacist’s high-level view of the product as a whole — what’s inside, the evidence for its stated use, how transparent the label is, and what safety data exists — so you can see the full picture in one place. It’s educational information from our licensed clinical databases and the clinical staff at HelloPharmacist — not medical advice — and we don’t sell or endorse products. Our editorial policy

The interaction bottom line Most serious interaction: Major

Resveratrol is a dietary supplement by NutraMedix with 2 active ingredients. Its ingredients are commonly taken for heart and blood vessel health, antioxidant support, anti-aging.Based on those ingredients, 1,373 medications have a known interaction with it, the most serious rated major. The ingredients most likely to interact are Red Wine Fruit Extract, Trans-Resveratrol. Use the checker below to test your specific medication, or read the full HelloPharmacist Interaction Report.

Jump to a section

Check Your Meds Against Resveratrol by NutraMedix

Ask about any prescription or over-the-counter medication and we check it for interactions with Resveratrol by NutraMedix — and tell you which ingredient is responsible.

Pharmacist-reviewed data Checks every ingredient Answer in seconds
Prefer a human? Send your question to our licensed pharmacists — free, answered by email within 24 hours.

HelloPharmacist Scorecard of Resveratrol by NutraMedix

Our pharmacy team’s full take, with four database checks built into the cards below — a summary of what is known, not a grade of the product itself.

From our pharmacy team — supplement deep dive

Generated from HelloPharmacist’s pharmacist-curated databases and editorial rules · Last generated Jul 11, 2026

What’s inside

Full disclosure
Ingredient Transparency · database check
Full

Every active ingredient lists its own amount on the label.

Why this rating?
  • The label discloses an exact amount for 2 of its 2 active ingredients.
  • No proprietary blends here — you can verify the dose of every single component.

This product contains 2 active ingredients: trans-resveratrol (a compound found in grapes and red wine) and red wine fruit extract. Resveratrol is the antioxidant compound researchers study most closely.

The product also has inactive ingredients—microcrystalline cellulose, a vegetable capsule, magnesium stearate, and silicon dioxide—that serve as binders and fillers.

Does it work?

Moderate evidence
Evidence for Intended Use · database check
By FDA rules, dietary supplements can’t claim to treat, cure, or prevent disease — so labels speak in careful marketing language. We discern each product’s intended use from its name, label claims, and label statements, then grade the clinical evidence for that use. How these ratings are computed
Moderate

Some clinical evidence supports this product's ingredients for its stated purpose, but it isn't conclusive.

Why this rating?
  • The label markets this product for: supports immune, antioxidant, and cardiovascular health.
  • We looked for evidence on: Cardiovascular disease (CVD), Atherosclerosis, Hypercholesterolemia, Hypertension, Congestive heart failure (CHF), Coronary artery disease — and 2 related terms.
  • The strongest evidence on file: Wine is rated "Possibly Effective" for Cardiovascular disease (CVD) (Natural Medicines).
  • Also on file: Resveratrol is rated "Possibly Ineffective" for Cardiovascular disease (CVD), Hypercholesterolemia.
  • Also on file: Resveratrol is rated "Insufficient Reliable Evidence To Rate" for Hypertension.

Trans-resveratrol shows possibly effective evidence for obesity and allergic rhinitis (hay fever), but the data suggests it's possibly ineffective for cardiovascular disease and high cholesterol. Red wine fruit extract carries possibly effective ratings for H. pylori infection, bone density (osteopenia), cardiovascular disease, and diabetes.

Evidence for each of these remains preliminary—these aren't proven treatments, and more research is needed.

The evidence, ingredient by ingredient Resveratrol Wine

How safe is it?

Well-documented data
Safety Information · database check
Well characterized

Adverse-effect, pregnancy, and general safety data are on file for most of these ingredients.

Why this rating?
  • We hold adverse-effect (side-effect) data for 2 of the 2 matched ingredients.
  • Pregnancy & breastfeeding safety ratings cover 2 of 2.
  • General safety write-ups exist for 2 of 2.
  • Remember: this measures how much safety information exists. Thin data is not the same as being safe.

Trans-resveratrol is generally well tolerated at typical supplement doses, though higher doses may cause digestive upset like diarrhea or gastrointestinal discomfort. A small number of people on dialysis have reported headache, fatigue, and memory loss, though the connection isn't proven.

One case of a mild skin rash occurred in a trial and resolved after stopping. Red wine fruit extract contains alcohol, which poses its own risks: it can harm health and lead to dependence even at moderate amounts, and it's associated with digestive upset, drowsiness, and blood sugar drops.

Some people allergic to sulfites or yeast may react to wine, and it can trigger asthma in people with a history of it. For pregnancy: there isn't enough safety data for concentrated resveratrol supplements—talk with your doctor or pharmacist for personalized advice.

Red wine (alcohol) is not safe in pregnancy at any amount. For breastfeeding: resveratrol data is insufficient—check with your doctor or pharmacist.

Red wine alcohol passes into breast milk; avoid it or carefully time and limit intake.

Side effects, ingredient by ingredient Resveratrol Wine

Meds to double-check

Major interaction found
Known Interaction Concern · database check
Major identified

At least one ingredient has a documented Major-severity interaction. Check your medications for a personalized result.

Why this rating?
  • 2 of the 2 matched ingredients can interact with medications — Resveratrol, Wine.
  • The most serious interaction on file is rated Major.
  • Some involve high-stakes drug classes: anticoagulant / antiplatelet drugs; immunosuppressants / transplant drugs; diabetes medications.
  • For scale: 1,374 individual medications appear in the full list. A big number alone doesn't make a product dangerous — what matters is whether YOUR medication is on it, so run yours through the interaction checker on this page.

Before you use this product, double-check if you're on erythromycin, aspirin, warfarin, cisapride, cyclosporine, disulfiram, phenytoin, or flibanserin—the red wine extract carries Major interactions with all of these. Also be cautious if you take anticoagulants or antiplatelet drugs (blood thinners) or drugs processed by your liver through CYP2C19, CYP1A2, CYP3A4, or CYP2E1 enzymes—resveratrol has Moderate interactions with those classes.

Check your own medication Run your meds through the checker above

The bottom line

Scorecard at a glanceFully disclosed formula with some supporting evidence for its stated purpose. Major medication interactions have been identified, and safety information is well characterized.

If you take erythromycin, aspirin, warfarin, or any of the other Major-interaction drugs listed above, this product is not appropriate for you. Even for others, resveratrol's effectiveness is preliminary and modest.

Talk to your pharmacist before starting, especially if you're on any blood thinners or medications processed through your liver.

Educational only — not medical advice; always confirm with your pharmacist. Our editorial policy · How we use AI

Assessment coverage: 2 of 2 active ingredients matched to our full ingredient reviews (monographs). Based on the product label dated Jul 24, 2025.

This Scorecard evaluates available label information, ingredient evidence, and known medication-safety considerations. It does not independently verify product identity, purity, potency, contamination, or manufacturing quality. How these ratings are computed

At a glance

General information

Key facts about Resveratrol, straight from the product label.

Brand NutraMedix
Barcode (UPC) 728650071507
Net contents 60 Vegetable Capsule(s)
Market status On market
Date entered into DSLD Jul 24, 2025
DSLD ID 334052
Product type Other Combinations
Supplement form Capsule
Dietary claims / uses All Other, Structure/Function
Intended target group(s) Adult (18 - 50 Years), Women (not pregnant or lactating), Gluten Free, Dairy Free
From the label
Everything in this section is reproduced from the manufacturer’s own product label — it’s the label speaking, not HelloPharmacist. We show it so you can see exactly what the maker states; we don’t verify or endorse those statements.

Supplement Facts

The label details for Resveratrol by NutraMedix, sourced from the NIH Dietary Supplement Label Database.

Supplement Facts

Daily Value (DV) Target Group(s):
Adults and children 4 or more years of age
Minimum serving Sizes:
1 Capsule(s)
Maximum serving Sizes:
1 Capsule(s)
Servings per container
60
UPC/BARCODE
728650071507
IngredientAmount% DV
Trans-Resveratrol200 mg--
Red Wine Fruit Extract25 mg--

Other ingredients: Microcrystalline Cellulose, Vegetable Capsule, Magnesium Stearate, Silicon Dioxide

Tap any ingredient to jump to its full detail below.

Label statements
These statements are the manufacturer’s wording, reproduced from the product label — the label is saying it, not HelloPharmacist. We don’t verify or endorse them.
Precautions

Keep out of reach of children

Do not use if pregnant or nursing.

Stop use if adverse reactions develop.

Storage

Storage: Keep tightly closed in a dry place at room temperature. (59-86°F or 15-30°C)

Suggested/Recommended/Usage/Directions

Suggested use: Take one capsule once or twice daily after a meal or as directed by your physician.

FDA Disclaimer Statement

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.

Formula

Resveratrol with red wine extract

Formulation

Supports immune, antioxidant, and cardiovascular health

Gluten free Soy free Dairy Free

FDA Statement of Identity

Dietary Supplement

Is this label outdated? Report a formula or label change and our pharmacy team will review it.

See for yourself

Resveratrol by NutraMedix label

The label scan from the NIH Dietary Supplement Label Database. Tap to enlarge.

Resveratrol label

Label images are published by the NIH Dietary Supplement Label Database for the version of this product on file. Always read your actual product label.

View the full label (PDF)
What’s inside

The Ingredients in Resveratrol by NutraMedix

These are the 2 active ingredients this product is made of. Select any to open its full monograph.

Serving size1 Capsule(s) Dosage formCapsule Servings per container60 Amounts shown are per serving.

Most supplement products combine several ingredients, and a medication can interact with the product through any one of them. Each ingredient below shows whether it has known drug interactions.

Trans-Resveratrol

Interacts with
822 drugs
200 mg per serving Form: Japanese Knotweed Root Extract

Resveratrol is a plant compound found in red grapes, berries, and peanuts that is popular for heart health, anti-aging, and antioxidant support. While...

Trans-Resveratrol monograph & interactions

Red Wine Fruit Extract

Interacts with
926 drugs
25 mg per serving Form: Vitis vinifera Fruit Extract

Wine is an alcoholic beverage made from fermented grapes and is not a true dietary supplement or medicine. Despite popular claims about heart benefits...

Red Wine Fruit Extract monograph & interactions

Other (inactive) ingredients: Microcrystalline Cellulose, Vegetable Capsule, Magnesium Stearate, Silicon Dioxide. These complete the product’s ingredient list but are not active constituents.

Interaction report

Resveratrol by NutraMedix Drug Interactions

Want to check YOUR meds against Resveratrol?

Ask about interactions with your drugs in plain English — “Can I take it with lisinopril?” — and we find you the answer in seconds, ingredient by ingredient.

 Go to the checker
1,373Drugs
656 Major 717 Moderate

Ingredients driving the most interactions

Red Wine Fruit Extract 926
Trans-Resveratrol 822

Individual Drug Interactions

The ingredients in Resveratrol interact with 1,373 drugs. Click any drug to see the details.

2 of the 2 ingredients in Resveratrol interact with drugs. Each result below shows which ingredient is responsible. Red Wine Fruit Extract Trans-Resveratrol

Each ingredient & the kinds of drugs it affects

For each ingredient in Resveratrol with known interactions, here are the types of medications they can affect. Open any type for the detail — or search your exact drug in the checker above.

Red Wine Fruit Extract37 drug types · 926 drugs

Aspirin

Concomitant use may increase the risk of gastrointestinal (GI) bleeding.
Concomitant use of aspirin with alcohol may increase the risk of GI bleeding.

Likelihood Probable Evidence C
Cisapride (Propulsid)

Concomitant use may increase blood alcohol levels and adverse effects.
Concomitant use of alcohol can increase blood alcohol levels and adverse effects. Also, red wine increases plasma cisapride concentrations, possibly by reducing metabolism.

Likelihood Probable Evidence B
Cns Depressants

Concomitant use may increase sedative and other adverse effects.
Concomitant use of alcohol with CNS depressants can increase sedative and other adverse effects, potentially through inhibition of the metabolism of certain CNS depressants.

Likelihood Likely Evidence C
Cyclosporine (Neoral, Sandimmune)

Red wine can reduce the levels and clinical effects of cyclosporine.
Red wine reduces plasma cyclosporine concentrations, possibly by reducing cyclosporine absorption. There is evidence the reduction in cyclosporine AUC by red wine is less in Asians (8% to 14%) than Caucasians (35% to 36%).

Likelihood Probable Evidence B
Disulfiram (Antabuse)

Concomitant use may cause a disulfiram reaction.
Disulfiram can cause a disulfiram reaction when taken with alcohol. Patients taking disulfiram should not consume any alcohol.

Likelihood Likely Evidence C
Erythromycin

Concomitant use may increase blood alcohol levels and adverse effects.
Concomitant use of erythromycin with alcohol can increase blood alcohol levels and adverse effects.

Likelihood Probable Evidence C
Felodipine (Plendil)

Consumption of red wine can rapidly increase felodipine levels and adverse effects.
Red wine taken on an empty stomach can cause "dose dumping" of extended-release felodipine, possibly by changing absorption or metabolism. Red wine can delay the appearance of felodipine in plasma until 4 hours after dosing and can rapidly increase its plasma concentration, producing peak serum levels 3 to 4 times higher than when felodipine is given with water. This can cause an increase in adverse effects 5 hours after dosing.

Likelihood Probable Evidence B
Flibanserin (Addyi)

Concomitant use increases the risk of severe hypotension and syncope.
Alcohol use is contraindicated in patients taking flibanserin due to the risk of severe hypotension and syncope.

Likelihood Probable Evidence A
Hepatotoxic Drugs

Concomitant use of alcohol with hepatotoxic drugs may increase the risk of hepatotoxicity.
Concomitant use of excessive amounts of alcohol with potentially hepatotoxic drugs can increase the risk of liver damage.

Likelihood Probable Evidence C
Monoamine Oxidase Inhibitors (Maois)

Concomitant use may cause hypertensive crisis.
Wine contains tyramine, which is metabolized by monoamine oxidase. Concurrent use of MAOIs with tyramine-containing beverages can lead to elevated levels of tyramine in the body. This can increase the effects of tyramine, which has been reported to cause hypertension, headache, and hypertensive crisis in numerous cases. Sensitivity to tyramine can increase up to 10-fold to 100-fold in people using an MAOI.

Likelihood Probable Evidence D
Nonsteroidal Anti-Inflammatory Drugs (Nsaids)

Concomitant use may increase the risk of gastrointestinal (GI) bleeding.
Concomitant use of NSAIDs with alcohol may increase the risk of GI bleeding.

Likelihood Probable Evidence C
Phenytoin (Dilantin)

Concomitant use may decrease the effectiveness of phenytoin.
Chronic, heavy alcohol use can induce the metabolism, reducing therapeutic effectiveness of phenytoin.

Likelihood Probable Evidence C
Warfarin (Coumadin)

Alcohol can alter the effects of warfarin, although the exact effect depends on the nature of alcohol consumption.
Acute alcohol intoxication can decrease metabolism and increase the effects of warfarin. In contrast, chronic, heavy alcohol use can induce metabolism of warfarin, reducing therapeutic effectiveness.

Likelihood Probable Evidence C
Acitretin (Soriatane)

Concomitant use increases the risk of long-term teratogenic effects.
Alcohol increases the transesterification of acitretin to etretinate, which is a teratogen that can remain in the body for years after discontinuation of acitretin. Patients of reproductive potential should avoid alcohol completely while taking acitretin and at least 2 months after discontinuation.

Likelihood Probable Evidence B
Antidiabetes Drugs

Concomitant use may interfere with blood glucose control.
Alcohol can impair gluconeogenesis and may increase the risk of acute hypoglycemia when used concomitantly with antidiabetes drugs. However, the carbohydrates in wine may also worsen glycemic control in patients with diabetes.

Likelihood Probable Evidence C
Antihypertensive Drugs

Theoretically, concomitant use may interfere with blood pressure control.
Clinical research suggests that consumption of alcohol can increase both systolic and diastolic blood pressure. However, acute alcohol intoxication can also increase the risk of hypotension and additive effects with antihypertensive drugs.

Likelihood Probable Evidence B
Bupropion (Wellbutrin)

Theoretically, concomitant use may increase the risk of adverse effects from alcohol.
In patients taking bupropion, there have been rare reports of adverse psychiatric events or reduced alcohol tolerance. Additionally, in chronic alcohol users, abrupt discontinuation of alcohol while taking bupropion may increase the risk of seizure.

Likelihood Possible Evidence D
Cefamandole (Mandol)

Concomitant use may cause a disulfiram-like reaction.
Cefamandole can cause a disulfiram-like reaction when taken with alcohol.

Likelihood Possible Evidence C
Cefoperazone (Cefobid)

Concomitant use may cause a disulfiram-like reaction.
Cefoperazone can cause a disulfiram-like reaction when taken with alcohol.

Likelihood Possible Evidence C
Cetirizine (Zyrtec)

Theoretically, concomitant use might increase the risk of CNS impairment.
Cetirizine may cause somnolence in some patients. There is some concern that taking cetirizine in conjunction with alcohol might reduce alertness and impair CNS performance.

Likelihood Possible Evidence D
Chlorpropamide (Diabinese)

Concomitant use may cause a disulfiram-like reaction.
Chlorpropamide can cause a disulfiram-like reaction when taken with alcohol.

Likelihood Probable Evidence C
Citalopram (Celexa)

Theoretically, concomitant use might increase the risk of adverse effects from alcohol.
Some case reports suggest that citalopram may reduce alcohol tolerance and increase the risk of adverse effects from alcohol.

Likelihood Possible Evidence D
Doxycycline (Vibramycin)

Chronic alcohol use might reduce the levels and clinical effects of doxycycline.
Although acute alcohol ingestion does not seem to significantly impact the pharmacokinetics of doxycycline, chronic alcohol ingestion has been shown to significantly reduce the half-life and serum concentration of doxycycline.

Likelihood Possible Evidence B
Eluxadoline (Viberzi)

Chronic or excessive alcohol use might increase the risk of pancreatitis from eluxadoline.
In clinical studies, the risk of pancreatitis with eluxadoline was increased in chronic alcohol users and in those with acute intake of 3 or more alcoholic beverages daily.

Likelihood Possible Evidence A
Griseofulvin (Fulvicin)

Concomitant use may cause a disulfiram-like reaction.
Griseofulvin can cause a disulfiram-like reaction, including tachycardia and facial flushing, when taken with alcohol.

Likelihood Possible Evidence C
Red Wine Fruit Extract full monograph & all 37 interactions

Trans-Resveratrol5 drug types · 822 drugs

Anticoagulant/Antiplatelet Drugs

Resveratrol may have antiplatelet effects and may increase the risk of bleeding if used with anticoagulant or antiplatelet drugs.
Resveratrol seems to have antiplatelet effects.

Likelihood Possible Evidence D
Cytochrome P450 1A2 (Cyp1A2) Substrates

Theoretically, resveratrol might increase levels of drugs metabolized by CYP1A2.
In vitro research shows that resveratrol can inhibit CYP1A2 enzymes. However, this interaction has not been reported in humans.

Likelihood Possible Evidence D
Cytochrome P450 2C19 (Cyp2C19) Substrates

Theoretically, resveratrol might increase levels of drugs metabolized by CYP2C19.
In vitro research shows that resveratrol can inhibit CYP2C19 enzymes. However, this interaction has not been reported in humans.

Likelihood Possible Evidence D
Cytochrome P450 2E1 (Cyp2E1) Substrates

Resveratrol might increase levels of drugs metabolized by CYP2E1.
In vitro research suggests that resveratrol inhibits CYP2E1 isoenzyme. Also, a pharmacokinetic study shows that taking resveratrol 500 mg daily for 10 days prior to taking a single dose of chlorzoxazone 250 mg increases the maximum concentration of chlorzoxazone by about 54%, the area under the curve of chlorzoxazone by about 72%, and the half-life of chlorzoxazone by about 35%. Chlorzoxazone is used as a probe drug for CYP2E1.

Likelihood Probable Evidence B
Cytochrome P450 3A4 (Cyp3A4) Substrates

Theoretically, resveratrol might increase levels of drugs metabolized by CYP3A4.
In vitro research shows that resveratrol can inhibit the CYP3A4 enzyme. However, clinical research shows that taking resveratrol 3000 mg daily for 8 weeks does not necessitate dose adjustments to medications metabolized by CYP3A4.

Likelihood Possible Evidence D
Trans-Resveratrol full monograph & interactions
The maker

Brand information

Manufacturer and brand details for Resveratrol, from the product label.

NutraMedix

See all NutraMedix products
Name
NutraMedix
City
Jupiter
State
Florida
ZipCode
33458
Phone Number
561-745-2917
Web Address
www.nutramedix.com
Pharmacist Counseling Corner

Resveratrol by NutraMedix: Common Questions

Does Resveratrol by NutraMedix interact with any medications?
Yes. Based on its ingredients, Resveratrol has a known interaction with 1,373 medications, including 656 rated major. Use the checker to see how it interacts with a specific drug.
How can one product interact with so many drugs?
Resveratrol contains 2 active ingredients, and an interaction can come from any of them. We check every ingredient, combine the results into one list per medication, and show which ingredient and mechanism is responsible.
Where does this information come from?
The product label data comes from the NIH Dietary Supplement Label Database (DSLD); the interaction data is built on the Natural Medicines database and reviewed by HelloPharmacist pharmacists.
Does this product actually work for weight loss or heart health?
The evidence for resveratrol is mixed. It shows possibly effective for obesity and hay fever, but possibly ineffective for heart disease and high cholesterol. The red wine extract has possibly effective evidence for heart disease and blood sugar, but these aren't proven treatments—the research is still developing. Talk to your pharmacist about whether it fits your goals.
Is it safe to take while pregnant or breastfeeding?
There's not enough data on resveratrol supplements in pregnancy to know either way—talk with your doctor or pharmacist. The red wine extract contains alcohol, which is not safe in pregnancy at any level. For breastfeeding, resveratrol data is insufficient—check with your doctor. Alcohol passes into breast milk, so red wine should be avoided or very carefully timed and limited.
What are the side effects?
At normal doses, trans-resveratrol is usually well tolerated. Higher doses may cause diarrhea and digestive upset. The red wine extract's side effects come mainly from its alcohol content—nausea, diarrhea, drowsiness, and flushing are common. Some people allergic to sulfites or yeast in wine may react, and it can trigger asthma in people with a history of it.
Can I take this with my blood thinner?
No—both ingredients can thin the blood, and this product carries Moderate interactions with anticoagulants and antiplatelet drugs. If you're on warfarin, aspirin, clopidogrel, or any blood thinner, check with your pharmacist before using this product.
Why is this product so hard to use with medications?
The red wine extract component carries major interactions with several common medications—erythromycin, aspirin, warfarin, and others—because alcohol changes how your liver metabolizes these drugs. Trans-resveratrol can also slow down liver enzymes that break down many medications, potentially raising their levels in your blood.
Is there alcohol in this supplement?
Yes, the red wine fruit extract contains alcohol. Wine carries risks including digestive upset, drowsiness, and blood sugar drops, and it can be habit-forming. If you're taking disulfiram (Antabuse) or flibanserin (Addyi), do not use this product.

Written and reviewed by the HelloPharmacist editorial staff. Our editorial policy

Not sure if Resveratrol is safe with your meds?

Our pharmacists answer your medication & supplement questions — free.

Ask a pharmacist

Label information is sourced from the NIH Dietary Supplement Label Database and reflects the product version on file; always read your actual product label. This page is for education only and is not a substitute for professional medical advice. Confirm with your pharmacist or doctor before combining supplements and medications.

Resveratrol label
Go deeper

The Full Monographs Behind Resveratrol’s Ingredients

Every ingredient we hold a full HelloPharmacist monograph for — uses, evidence, safety, and the complete interaction list.

Herb & supplement monograph

Resveratrol

Interacts with 822 drugs

Resveratrol is a plant compound found in red grapes, berries, and peanuts that is popular for heart health, anti-aging, and antioxidant support. While lab and animal studies are promising, s...

Read the full Resveratrol monograph → Herb & supplement monograph

Wine

Interacts with 926 drugs

Wine is an alcoholic beverage made from fermented grapes and is not a true dietary supplement or medicine. Despite popular claims about heart benefits, the alcohol it contains carries real h...

Read the full Wine monograph →
Sources

Sources & How We Checked

Resveratrol's label data comes from the NIH Dietary Supplement Label Database; the ingredient interaction data is from the Natural Medicines database, reviewed by our pharmacists.

Content is written and reviewed by licensed HelloPharmacist pharmacists. See our data sources and editorial standards for how this information is built and checked.

The 97 references behind this product’s interaction data

Every citation that drives the interaction findings for this product’s ingredients, from the evidence-graded Natural Medicines (TRC Healthcare) database. Open an ingredient to browse its citations — links open the study on PubMed or the publisher’s site.

Resveratrol 24 references
  1. Soleas GJ, Diamandis EP, Goldberg DM. Resveratrol: a molecule whose time has come? And gone? Clin Biochem 1997;30:91-113.
  2. Pace-Asciak CR, Rounova O, Hahn SE, et al. Wines and grape juices as modulators of platelet aggregation in healthy human subjects. Clin Chim Acta 1996;246:163-82. PubMed
  3. Bertelli AA, Giovannini L, Bernini W, et al. Antiplatelet activity of cis-resveratrol. Drugs Exp Clin Res 1996;22:61-3.
  4. Pace-Asciak CR, Hahn S, Diamandis EP, et al. The red wine phenolics trans-resveratrol and quercetin block human platelet aggregation and eicosanoid synthesis: implications for protection against coronary heart disease. Clin Chim Acta 1995;235:207-19.
  5. Bertelli A, Bertelli AA, Gozzini A, Giovannini L. Plasma and tissue resveratrol concentrations and pharmacological activity. Drugs Exp Clin Res 1998;24:133-8.
  6. Bertelli AA, Giovannini L, Giannessi D, et al. Antiplatelet activity of synthetic and natural resveratrol in red wine. Int J Tissue React 1995;17:1-3.
  7. Piver B, Berthou F, Dreano Y, Lucas D. Inhibition of CYP3A, CYP1A and CYP2E1 activities by resveratrol and other non volatile red wine components. Toxicol Lett 2001;125:83-91. PubMed
  8. Chang, T. K., Chen, J., and Lee, W. B. Differential inhibition and inactivation of human CYP1 enzymes by trans-resveratrol: evidence for mechanism-based inactivation of CYP1A2. J.Pharmacol.Exp.Ther. 2001;299(3):874-882.
  9. Dobrydneva, Y., Williams, R. L., and Blackmore, P. F. trans-Resveratrol inhibits calcium influx in thrombin-stimulated human platelets. Br.J.Pharmacol. 1999;128(1):149-157.
  10. Kirk, R. I., Deitch, J. A., Wu, J. M., and Lerea, K. M. Resveratrol decreases early signaling events in washed platelets but has little effect on platalet in whole food. Blood Cells Mol.Dis. 2000;26(2):144-150.
  11. Zbikowska, H. M. and Olas, B. Antioxidants with carcinostatic activity (resveratrol, vitamin E and selenium) in modulation of blood platelet adhesion. J Physiol Pharmacol. 2000;51(3):513-520.
  12. Olas, B., Wachowicz, B., Saluk-Juszczak, J., and Zielinski, T. Effect of resveratrol, a natural polyphenolic compound, on platelet activation induced by endotoxin or thrombin. Thromb.Res 8-15-2002;107(3-4):141-145. PubMed
  13. Yu, C., Shin, Y. G., Kosmeder, J. W., Pezzuto, J. M., and van Breemen, R. B. Liquid chromatography/tandem mass spectrometric determination of inhibition of human cytochrome P450 isozymes by resveratrol and resveratrol-3-sulfate. Rapid Commun.Mass Spectro PubMed
  14. Ma, Z. H. and Ma, Q. Y. Resveratrol: a medical drug for acute pancreatitis. World J Gastroenterol. 6-7-2005;11(21):3171-3174. PubMed
  15. la, Porte C., Voduc, N., Zhang, G., Seguin, I., Tardiff, D., Singhal, N., and Cameron, D. W. Steady-State pharmacokinetics and tolerability of trans-resveratrol 2000 mg twice daily with food, quercetin and alcohol (ethanol) in healthy human subjects. Cli PubMed
  16. Brown, V. A., Patel, K. R., Viskaduraki, M., Crowell, J. A., Perloff, M., Booth, T. D., Vasilinin, G., Sen, A., Schinas, A. M., Piccirilli, G., Brown, K., Steward, W. P., Gescher, A. J., and Brenner, D. E. Repeat dose study of the cancer chemopreventive
  17. Pendurthi, U. R., Williams, J. T., and Rao, L. V. Resveratrol, a polyphenolic compound found in wine, inhibits tissue factor expression in vascular cells : A possible mechanism for the cardiovascular benefits associated with moderate consumption of wine. PubMed
  18. Chachay VS, Macdonald GA, Martin JH, Whitehead JP, O'Moore-Sullivan TM, Lee P, Franklin M, Klein K, Taylor PJ, Ferguson M, Coombes JS, Thomas GP, Cowin GJ, Kirkpatrick CM, Prins JB, Hickman IJ. Resveratrol does not benefit patients with nonalcoholic fatty
  19. Bedada SK, Neerati P. Resveratrol Pretreatment Affects CYP2E1 Activity of Chlorzoxazone in Healthy Human Volunteers. Phytother Res. 2016;30(3):463-8. PubMed
  20. Lin CT, Sun XY, Lin AX. Supplementation with high-dose trans-resveratrol improves ultrafiltration in peritoneal dialysis patients: a prospective, randomized, double-blind study. Ren Fail. 2016;38(2):214-21. PubMed
  21. Li Q, Yang G, Xu H, Tang S, Lee WY. Effects of resveratrol supplementation on bone quality: a systematic review and meta-analysis of randomized controlled trials. BMC Complement Med Ther 2021;21(1):214. PubMed
  22. McCreary MR, Schnell PM, Rhoda DA. Randomized double-blind placebo-controlled proof-of-concept trial of resveratrol for outpatient treatment of mild coronavirus disease (COVID-19). Sci Rep 2022;12(1):10978. PubMed
  23. Abdelhaleem IA, Brakat AM, Adayel HM, Asla MM, Rizk MA, Aboalfetoh AY. The effects of resveratrol on glycemic control and cardiometabolic parameters in patients with T2DM: A systematic review and meta-analysis. Med Clin (Barc) 2022;158(12):576-585. PubMed
  24. Badaoui A. Allergic contact dermatitis to resveratrol and Scutellaria baicalensis root extract in a cosmetic product. Contact Dermatitis 2022.

See these in context on the Resveratrol monograph →

Wine 73 references
  1. Burnham TH, ed. Drug Facts and Comparisons, Updated Monthly. Facts and Comparisons, St. Louis, MO.
  2. Hart CL, Smith GD, Hole DJ, Hawthorne VM. Alcohol consumption and mortality from all causes, coronary heart disease, and stroke: results from a prospective cohort study of Scottish men with 21 years of follow up. BMJ 1999;318:1725-9. PubMed
  3. Offman EM, Freeman DJ, Dresser GK, et al. Cisapride interaction with grapefruit juice and red wine. Clin Pharmacol Ther 2000;67:110 (abstract PI-83).
  4. Tsunoda SM, Christians U, Velez RL, et al. Red wine (RW) effects on cyclosporine (CyA) metabolites. Clin Pharmacol Ther 2000;67:150 (abstract PIII-35).
  5. Tsunoda SM, Harris RZ, Velez RL, et al. Red wine (RW) effects on cyclosporine (CyA) Pharmacokinetics. Clin Pharmacol Ther 1998;65:159 (abstract PII-51). DOI
  6. Pearson TA. Alcohol and heart disease. Circulation 1996;94:3023-5. PubMed
  7. Fraser AG. Pharmacokinetic interactions between alcohol and other drugs. Clin Pharmacokinet 1997;33:79-90. PubMed
  8. Stampfer MJ, Colditz GA, Willett WC, et al. A prospective study of moderate alcohol consumption and the risk of coronary disease and stroke in women. N Engl J Med 1988;319:267-73. PubMed
  9. Vally H, de Klerk N, Thompson PJ. Alcoholic drinks: important triggers for asthma. J Allergy Clin Immunol 2000;105:462-7. PubMed
  10. Thun MJ, Peto R, Lopez AD, et al. Alcohol consumption and mortality among middle-aged and elderly US adults. N Engl J Med 1997;337:1705-14.
  11. Goldberg I, Mosca L, Piano MR, Fisher EA. AHA Science Advisory: Wine and your heart: a science advisory for healthcare professionals from the Nutrition Committee, Council on Epidemiology and Prevention, and Council on Cardiovascular Nursing of the America
  12. Michaud DS, Giovannucci E, Willett WC, et al. Coffee and alcohol consumption and risk of pancreatic cancer in two prospective United States cohorts. Cancer Epidemiol Biomarkers Prev 2001;10:429-37.
  13. Dufour MC. If you drink alcoholic beverages do so in moderation: what does this mean? J Nutr 2001;131:552S-61S. PubMed
  14. Thadhani R, Camargo CA, Stampfer MJ, et al. Prospective study of moderate alcohol consumption and risk of hypertension in young women. Arch Intern Med 2002;162:569-74. PubMed
  15. Mukamal KJ, Longstreth WT, Mittleman MA. Alcohol consumption and subclinical findings on magnetic resonance imaging of the brain in older adults: the cardiovascular health study. Stroke 2001;32:1939-46. PubMed
  16. Bosetti C, La Vecchia C, Negri E, Franceschi S. Wine and other types of alcoholic beverages and the risk of esophageal cancer. Eur J Clin Nutr 2000;54:918-20. PubMed
  17. Singletary KW, Gapstur SM. Alcohol and breast cancer: review of epidemiologic and experimental evidence and potential mechanisms. JAMA 2001;286:2143-51. PubMed
  18. Tsunoda SM, Harris RZ, Christians U, et al. Red wine decreases cyclosporine bioavailabity. Clin Pharmacol Ther 2001;70:462-7.
  19. Bosetti C, La Vecchia C, Negri E, Franceschi S. Wine and other types of alcoholic beverages and the risk of esophageal cancer. Eur J Clin Nutr 2000;54:918-20. PubMed
  20. Kato H, Yoshikawa M, Miyazaki T, et al. Expression of p53 protein related to smoking and alcoholic beverage drinking habits in patients with esophageal cancers. Cancer Lett 2001;167:65-72. PubMed
  21. Singletary KW, Gapstur SM. Alcohol and breast cancer: review of epidemiologic and experimental evidence and potential mechanisms. JAMA 2001;286:2143-51. PubMed
  22. Duncan BB, Chambless LE, Schmidt MI, et al. Association of the waist-to-hip ratio is different with wine than with beer or hard liquor consumption. Am J Epidemiol 1995;142:1034-8. DOI
  23. Bobak M, Skodova Z, Marmot M. Beer and obesity: a cross-sectional study. Eur J Clin Nutr 2003;57:1250-53. PubMed
  24. Koh-Banerjee P, Chu N, Spiegelman D, et al. Prospective study of the association of changes in dietary intake, physicial activity, alcohol consumption, and smoking with 9-y gain in waist circumference among 16 587 US men. Am J Clin Nutr 2003;78:719-27..
  25. Mennella J. Alcohol's effect on lactation. Alcohol Res Health 2001;25:230-4.
  26. Bailey DG, Dresser GK, Bend JR. Bergamottin, lime juice, and red wine as inhibitors of cytochrome P450 3A4 activity: comparison with grapefruit juice. Clin Pharmacol Ther 2003;73:529-37. PubMed
  27. Launoy, G., Milan, C., Day, N. E., Faivre, J., Pienkowski, P., and Gignoux, M. Oesophageal cancer in France: potential importance of hot alcoholic drinks. Int J Cancer 6-11-1997;71(6):917-923. DOI
  28. Lijinsky, W. N-Nitroso compounds in the diet. Mutat.Res 7-15-1999;443(1-2):129-138. PubMed
  29. Seiler, C. [Alcohol, the heart and cardiovascular system]. Ther Umsch. 2000;57(4):200-204.
  30. Altieri, A., Bosetti, C., Gallus, S., Franceschi, S., Dal, Maso L., Talamini, R., Levi, F., Negri, E., Rodriguez, T., and La, Vecchia C. Wine, beer and spirits and risk of oral and pharyngeal cancer: a case-control study from Italy and Switzerland. Oral PubMed
  31. Bode, C. and Bode, J. C. Alcohol's role in gastrointestinal tract disorders. Alcohol Health Res World 1997;21(1):76-83.
  32. Zilkens, R. R., Burke, V., Hodgson, J. M., Barden, A., Beilin, L. J., and Puddey, I. B. Red wine and beer elevate blood pressure in normotensive men. Hypertension 2005;45(5):874-879. PubMed
  33. Mukamal, K. J., Maclure, M., Muller, J. E., and Mittleman, M. A. Binge drinking and mortality after acute myocardial infarction. Circulation 12-20-2005;112(25):3839-3845. PubMed
  34. Pehl, C., Wendl, B., and Pfeiffer, A. White wine and beer induce gastro-oesophageal reflux in patients with reflux disease. Aliment.Pharmacol Ther 6-1-2006;23(11):1581-1586. PubMed
  35. Chao, C. Associations between beer, wine, and liquor consumption and lung cancer risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev 2007;16(11):2436-2447. PubMed
  36. Bushman, B. J. and Cooper, H. M. Effects of alcohol on human aggression: an integrative research review. Psychol.Bull 1990;107(3):341-354.
  37. Carstensen, J. M., Bygren, L. O., and Hatschek, T. Cancer incidence among Swedish brewery workers. Int J Cancer 3-15-1990;45(3):393-396. PubMed
  38. Potter, J. F., Watson, R. D., Skan, W., and Beevers, D. G. The pressor and metabolic effects of alcohol in normotensive subjects. Hypertension 1986;8(7):625-631. PubMed
  39. Puddey, I. B., Beilin, L. J., Vandongen, R., Rouse, I. L., and Rogers, P. Evidence for a direct effect of alcohol consumption on blood pressure in normotensive men. A randomized controlled trial. Hypertension 1985;7(5):707-713. PubMed
  40. Puddey, I. B., Beilin, L. J., Vandongen, R., and Rouse, I. L. A randomized controlled trial of the effect of alcohol consumption on blood pressure. Clin Exp Pharmacol Physiol 1985;12(3):257-261. PubMed
  41. Wellmann, K. F. ["Biere au cobalt". Remarks on the "Quebec myocardosis of beer drinker"]. Dtsch.Med Wochenschr. 3-15-1968;93(11):500-501.
  42. Bechetoille, A., Ebran, J. M., Allain, P., and Mauras, Y. [Therapeutic affect of zinc sulfate on central scotoma due to optic neuropathy of alcohol and tobacco abuse]. J Fr.Ophtalmol. 1983;6(3):237-242.
  43. Balazs, T. and Herman, E. H. Toxic cardiomyopathies. Ann Clin Lab Sci 1976;6(6):467-476.
  44. Lauwerys, R. and Lison, D. Health risks associated with cobalt exposure--an overview. Sci Total Environ 6-30-1994;150(1-3):1-6. PubMed
  45. Goldbohm, R. A., Van den Brandt, P. A., Van, 't, V, Dorant, E., Sturmans, F., and Hermus, R. J. Prospective study on alcohol consumption and the risk of cancer of the colon and rectum in the Netherlands. Cancer Causes Control 1994;5(2):95-104. PubMed
  46. Anderson, P., Cremona, A., Paton, A., Turner, C., and Wallace, P. The risk of alcohol. Addiction 1993;88(11):1493-1508.
  47. Leira, R. and Rodriguez, R. [Diet and migraine]. Rev Neurol. 1996;24(129):534-538.
  48. Glynn, S. A., Albanes, D., Pietinen, P., Brown, C. C., Rautalahti, M., Tangrea, J. A., Taylor, P. R., and Virtamo, J. Alcohol consumption and risk of colorectal cancer in a cohort of Finnish men. Cancer Causes Control 1996;7(2):214-223. PubMed
  49. Ferraroni, M., Decarli, A., Franceschi, S., and La, Vecchia C. Alcohol consumption and risk of breast cancer: a multicentre Italian case-control study. Eur J Cancer 1998;34(9):1403-1409. PubMed
  50. Chen JY, Zhu HC, Guo Q, et al. Dose-Dependent Associations between Wine Drinking and Breast Cancer Risk - Meta-Analysis Findings. Asian Pac J Cancer Prev. 2016;17(3):1221-33. PubMed
  51. Miura K, Zens MS, Peart T, et al. Alcohol consumption and risk of melanoma among women: pooled analysis of eight case-control studies. Arch Dermatol Res. 2015;307(9):819-28. PubMed
  52. Rivera A, Nan H, Li T, Qureshi A, Cho E. Alcohol Intake and Risk of Incident Melanoma: A Pooled Analysis of Three Prospective Studies in the United States. Cancer Epidemiol Biomarkers Prev. 2016;25(12):1550-1558. PubMed
  53. Shufelt C, Merz CN, Yang Y, et al. Red versus white wine as a nutritional aromatase inhibitor in premenopausal women: a pilot study. J Womens Health (Larchmt). 2012;21(3):281-4. PubMed
  54. VanDenBerg CM, Blob LF, Kemper EM, Azzaro AJ. Tyramine pharmacokinetics and reduced bioavailability with food. J Clin Pharmacol. 2003;43(6):604-9. DOI
  55. Peet M, Yates RA, Carroll JA, Middlemiss DN. The interaction of tyramine with a single dose of tranylcypromine in healthy volunteers. Br J Clin Pharmacol. 1981;11(2):212-4. PubMed
  56. Rapaport MH. Dietary restrictions and drug interactions with monoamine oxidase inhibitors: the state of the art. J Clin Psychiatry. 2007;68 Suppl 8:42-6.
  57. Miraghajani M, Momenyan S, Arab A, Hasanpour Dehkordi A, Symonds ME. Blueberry and cardiovascular disease risk factors: a systematic review and meta-analysis of randomized controlled trials. Complement Ther Med 2020;53:102389. PubMed
  58. German-Sanchez A, Alonso-Llamazares A, Garcia-Gonzalez F, Matala-Ahmed B, Bartolome-Zavala B, Antepara-Ercoreca I. Allergy to beer and wine caused by Saccharomyces cerevisiae in a patient sensitized to fungi. J Investig Allergol Clin Immunol 2021. PubMed
  59. Glucophage XR (metformin) prescribing information. Bristol-Myers Squibb Company. Princeton, NJ, May 2018. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020357s034,021202s018lbl.pdf
  60. Solosec (secnidazole) prescribing information. Lupin Pharmaceuticals, Inc. Baltimore, MD, January 2022. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209363Orig1s014s016lbl.pdf
  61. Tindamax (tinidazole) prescribing information. Mission Pharmaceutical Company. San Antonio, TX, December 2021. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021618s008lbl.pdf
  62. Mergenhagen KA, Wattengel BA, Skelly MK, Clark CM, Russo TA. Fact versus Fiction: a Review of the Evidence behind Alcohol and Antibiotic Interactions. Antimicrob Agents Chemother. 2020;64(3):e02167-19. PubMed
  63. Flagyl (metronidazole) prescribing information. Pfizer Labs. New York, NY, December 2021. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/012623s069lbl.pdf
  64. Workowski KA, Bachmann LH, Chan PA, et al. Sexually transmitted infections treatment guidelines, 2021. MMWR Recomm Rep. 2021;70(4):1-187. PubMed
  65. Flagyl (metronidazole) prescribing information [CANADA]. Odan Labs. Pointe-Claire, QC H9R 2Y6. January 2018. Available at: https://pdf.hres.ca/dpd_pm/00044072.PDF
  66. Addyi (flibanserin) prescribing information. Sprout Pharmaceuticals, Inc. Raleigh, NC, September 2021. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/022526s010lbl.pdf
  67. Soriatane (Acitretin) prescribing information. Stiefl Laboratories, Inc. Research Triangle Park, NC, September 2017. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/019821s028lbl.pdf
  68. Viberzi (Eluxadoline) prescribing information. Allergan USA, Inc. Irvine, CA, June 2020. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/206940s007lbl.pdf
  69. Chantix (Varenicline) prescribing information. Pfizer Labs, Inc. New York, NY, February 2019. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021928s048lbl.pdf
  70. Zyrtec (Cetirizine) prescribing information. Pfizer Labs, Inc. New York, NY, October 2002. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/19835s15,%2020346s8lbl.pdf
  71. Wellbutrin XL (Bupropion) prescribing information. GlaxoSmithKline LLC. Research Triangle Park, NC, March 2022. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021515s044lbl.pdf
  72. Fetzima (Levomilnacipran) prescribing information. Allergan USA, Inc. Madison, NJ, September 2021. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/204168s007lbl.pdf
  73. Xyzal (Levocetirizine) prescribing information. UCB, Inc. April 2019. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022064s038,022157s020lbl.pdf

See these in context on the Wine monograph →

Parts of this content are provided by the Therapeutic Research Center, LLC.

DISCLAIMER: Currently this does not check for drug-drug interactions. This is not an all-inclusive comprehensive list of potential interactions and is for informational purposes only. Not all interactions are known or well-reported in the scientific literature, and new interactions are continually being reported. Input is needed from a qualified healthcare provider including a pharmacist before starting any therapy. Application of clinical judgment is necessary.

© 2021 Therapeutic Research Center, LLC

Keep exploring
Supplement interaction checker › Check any supplement or product against your medications Drug–drug interactions › Check two or more of your medications against each other Browse medications A–Z › Every drug we've checked against herbs & supplements NDC & pricing lookup › Find a drug’s NDCs, packaging and costs Ask a pharmacist › Free, personal answer from our licensed team